American Conference Institute’s 3nd West Coast Edition: Paragraph IV Disputes
The must-attend event for litigators from brand name and generic companies to share insights into increasingly high-stakes and complicated Hatch-Waxman litigation.
With hundreds of billions of dollars at stake as blockbuster drugs go off patent in 2014, Hatch-Waxman litigation will only intensify. Brand name manufacturers are struggling to fill a drying pipeline and extend patent life through other statutory and regulatory conventions. Meanwhile, generics eye the ultimate Hatch-Waxman prize of 180-day exclusivity— knowing that such opportunities in the future may be short-lived as there will be few patented drug products worth coveting.